Serina Therapeutics, Inc. · AMEX:SER
Serina Therapeutics — Investor Presentation (September 2026)
20 slides from Serina Therapeutics's investor presentation, September 2026
Slide 1: POZ Platform
® POZ Platform • Next Generation Drug Product Optimization Platform • Enabling Improvements of Multiple Drug Modalities CNS small molecule optimization – POZ / LNP - immune silent, payload POZ / ADC – enabling novel payloads / Lead asset in clinic agnostic delivery mechanisms Non-confidential invest
Slide 2: Forward Looking Statements
This presentation contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “
Slide 3: Enabling better CNS medicines from proven molecules
Enabling better CNS medicines from proven molecules SER-252 SER-270 SER-290 POZ-apomorphine POZ-DHTB / VMAT2i POZ-undisclosed Advanced Parkinson’s Tardive dyskinesia / Undisclosed CNS disease movement disorders indication Phase 1b study underway IND-enabling planning IND-enabling planning Lead asset
Slide 4: Small Molecule Optimization: SER-252-led, milestone-driven CNS story
Small Molecule Optimization: SER-252-led, milestone-driven CNS story Clinical-stage Proven-molecule FDA-aligned Near-term Repeatable lead asset strategy 505(b)(2) NDA de-risking CNS model path events SER-252 is in a Apomorphine is Known API, prior SAD data can address SER-270 and SER-290 registratio
Slide 5: Why now: clinical execution and financing strengthened in 2026
Why now: clinical execution and financing strengthened in 2026 SER-252 has moved from regulatory alignment into clinical execution with defined near-term milestones. SER-252 in clinic Next safety gate First patient dosed in February 2026 in SAD Cohort 1 blinded safety/tolerability/PK review SAD arm
Slide 6: SER-252 at a glance
SER-252 at a glance Lead product candidate designed to make continuous dopaminergic stimulation easier to deliver in advanced Parkinson’s disease. POZ-apomorphine Apomorphine is a clinically active dopamine agonist, but current continuous products are limited by pump burden and local administration-
Slide 7: Advanced Parkinson's disease creates a defined unmet need
Advanced Parkinson’s disease creates a defined unmet need As disease advances, oral regimens often become insufficient and patients move toward high-burden continuous therapies. The treatment journey creates a clear target population: More frequent OFF time and less predictable symptom control ~250K
Slide 8: Continuous dopaminergic stimulation (CDS) is becoming a commercial category
Continuous dopaminergic stimulation (CDS) is becoming a commercial category The market is being built by recently approved products, creating a clearer path for differentiated entrants. 2.5 ~$2.1B 2 ~$1.8B Existing launches validate demand for continuous therapy, while highlighting the 1.5 importanc
Slide 9: Approved continuous therapies validate demand, but leave room for improvement
Approved continuous therapies validate demand, but leave room for Market validation improvement Established continuous levodopa/carbidopa therapy. Subcutaneous continuous levodopa/carbidopa product. Apomorphine confirms clinical utility of continuous dopamine agonist delivery. Remaining limitation S
Slide 10: SER-252 target product profile: simpler continuous therapy
SER-252 target product profile: simpler continuous therapy The product is being designed to deliver continuous therapy through a compact on-body system with brief wear time. 2x weekly No tubing on-body delivery compact wearable device No visible needle ~10 minutes designed for simple use wear time p
Slide 11: SER-252's convenience + tolerability profile stands apart from the approved options
SER-252’s convenience + tolerability profile stands apart from the approved options SER-252 (investigational) Vyalev (Abbvie) Onapgo (Supernus) Duopa / Duodopa (Abbvie) Foscarbidopa/foslevodopa SC Mechanism POZ-apomorphine SC injection Apomorphine SC infusion Carbidopa/levodopa intestinal gel infusi
Slide 12: SER-252's near-term data should begin answering the central questions that drive value creation
Safety / Can early cohorts show an acceptable safety 01 Tolerability profile in advanced PD patients? SER-252’s near- PK Does SER-252 generate controlled exposure term data should Profile consistent with continuous dopaminergic stimulation? 02 begin answering the central Skin Tolerability Does NHP i
Slide 13: POZ can turn known active drugs into differentiated products
POZ can turn known active drugs into differentiated products The platform can re-engineer clinically understood molecules into more usable product profiles Known Active Drug POZ Conjugate Clinically validated molecule Drug attached to POZ through with established pharmacology. cleavable linkers and
Slide 14: A development model designed to reduce risk and capital intensity
A development model Known API, prior human POZ PK proof and FDA designed to reduce risk alignment form a layered de-risking stack. and capital intensity Biology PK / Platform Regulatory Device Commercial Risk Risk Risk Risk Risk Known apomorphine Prior SER-214 Phase FDA aligned on enFuse has CDS cat
Slide 15: SER-252 Phase 1b registrational study is underway
First patient dosed February 2026; Status Cohort 1 n=8 dosing completed July 2026 SER-252 Phase 1b registrational study is underway Design Randomized, double-blind, placebo-controlled SAD and MAD components. The study is designed to generate safety, tolerability, PK and exploratory clinical Up to fi
Slide 16: Value-inflection milestones
Value-inflection milestones Clinical, regulatory and product-development milestones reduce risk in sequence before approval Cohort 1/ SAD Data MAD EOP2 NDA SMC Review Package Data Interaction Path Initial safety and Early PK, dose Repeat dosing, Refines remaining Registration tolerability gate; beha
Slide 17: SER-252 targets a large, underpenetrated opportunity
SER-252 $1.8B $2.7B ~250K targets a large, base-case peak annual upside peak annual sales advanced PD patients underpenetrated sales opportunity in US/EU4+UK opportunity if SER-252 further expands the inadequately controlled on oral therapy in advanced PD target market US/EU4+UK opportunity Clinical
Slide 18: Key clinical translation question: can SER-252 avoid apomorphine infusion limitations?
Why this matters Apomorphine is clinically active, but continuous infusion has been limited by short half-life, daily pump burden and serious local Key clinical administration-site reactions. translation question: Preclinical differentiation signal can SER-252 avoid NHP studies in company materials
Slide 19: Execution support: pipeline repeatability, financing and leadership
Execution support: SER-252 remains the priority; follow-on assets, recent financing and experienced leadership support pipeline repeatability, the next chapter. financing and leadership PIPELINE FINANCING SER-252 SER-270 SER-290 $21.2M POZ-apomorphine POZ-DHTB / VMAT2i POZ-undisclosed March/April 20
Slide 20: SER-252 first; platform upside without loss of focus
SER-252 first; platform upside without loss of focus Serina is a lead-asset execution story supported by a repeatable product-optimization platform. What Matters Now Serina builds better CNS medicines from proven Cohort 1 safety/tolerability blinded SMC review and advancement to Cohort 2 approved mo
Serina Therapeutics — Investor Presentation (September 2026) on 6ix